JP2019517790A - ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体 - Google Patents

ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体 Download PDF

Info

Publication number
JP2019517790A
JP2019517790A JP2018559282A JP2018559282A JP2019517790A JP 2019517790 A JP2019517790 A JP 2019517790A JP 2018559282 A JP2018559282 A JP 2018559282A JP 2018559282 A JP2018559282 A JP 2018559282A JP 2019517790 A JP2019517790 A JP 2019517790A
Authority
JP
Japan
Prior art keywords
seq
sequence
tcr
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517790A5 (enExample
Inventor
エルス マーリット インダーベルグ，
エルス マーリット インダーベルグ，
グスタフ ガウダーナック，
グスタフ ガウダーナック，
セバスチャン ヴェルクリ，
セバスチャン ヴェルクリ，
グンナール クヴァルハイム，
グンナール クヴァルハイム，
Original Assignee
オスロ ウニヴェルスィテーツスィーケフース ホーエフ
オスロ ウニヴェルスィテーツスィーケフース ホーエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オスロ ウニヴェルスィテーツスィーケフース ホーエフ, オスロ ウニヴェルスィテーツスィーケフース ホーエフ filed Critical オスロ ウニヴェルスィテーツスィーケフース ホーエフ
Publication of JP2019517790A publication Critical patent/JP2019517790A/ja
Publication of JP2019517790A5 publication Critical patent/JP2019517790A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
JP2018559282A 2016-05-09 2017-05-09 ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体 Pending JP2019517790A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII
GB1608052.5 2016-05-09
PCT/EP2017/061087 WO2017194555A1 (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII

Publications (2)

Publication Number Publication Date
JP2019517790A true JP2019517790A (ja) 2019-06-27
JP2019517790A5 JP2019517790A5 (enExample) 2020-06-18

Family

ID=56297359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559282A Pending JP2019517790A (ja) 2016-05-09 2017-05-09 ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体

Country Status (13)

Country Link
US (1) US20190336529A1 (enExample)
EP (1) EP3455249B1 (enExample)
JP (1) JP2019517790A (enExample)
KR (1) KR20190016507A (enExample)
CN (1) CN109328196B (enExample)
AU (1) AU2017261684A1 (enExample)
CA (1) CA3024555A1 (enExample)
EA (1) EA201892217A1 (enExample)
GB (1) GB201608052D0 (enExample)
IL (1) IL262873A (enExample)
MX (1) MX2018013581A (enExample)
SG (1) SG11201809716VA (enExample)
WO (1) WO2017194555A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724043B2 (en) 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
EP3854802A4 (en) * 2018-09-21 2022-10-12 XLifeSc, Ltd. HIGH AFFINE T-CELL RECEPTOR FOR RECOGNIZING AN AFP ANTIGEN
WO2020201527A1 (en) * 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
GB201907663D0 (en) 2019-05-30 2019-07-17 Ab Mavatar Method for diagnosing colorectal cancer
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
CA3221568A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Chimeric antigen receptor to target hla-g-positive cancers
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
AU2024312524A1 (en) * 2023-06-20 2026-01-22 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517240A (ja) * 1998-06-08 2002-06-18 トランジェーヌ ＴＧＦβＲＩＩレセプターの核酸配列、コードされたペプチドおよび使用
JP2002519999A (ja) * 1998-05-08 2002-07-09 ノルスク・ヒドロ・アーエスアー ペプチド
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012001278A (es) * 2009-07-29 2012-03-16 Glaxo Group Ltd Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
EP2714735B1 (en) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519999A (ja) * 1998-05-08 2002-07-09 ノルスク・ヒドロ・アーエスアー ペプチド
JP2002517240A (ja) * 1998-06-08 2002-06-18 トランジェーヌ ＴＧＦβＲＩＩレセプターの核酸配列、コードされたペプチドおよび使用
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY, vol. 6, 4, JPN7021001574, 2017, pages 1302631, ISSN: 0004503210 *

Also Published As

Publication number Publication date
SG11201809716VA (en) 2018-11-29
EP3455249A1 (en) 2019-03-20
CN109328196B (zh) 2022-11-01
EA201892217A1 (ru) 2019-08-30
US20190336529A1 (en) 2019-11-07
WO2017194555A1 (en) 2017-11-16
CA3024555A1 (en) 2017-11-16
MX2018013581A (es) 2019-07-04
IL262873A (en) 2019-01-31
KR20190016507A (ko) 2019-02-18
AU2017261684A1 (en) 2018-12-13
CN109328196A (zh) 2019-02-12
GB201608052D0 (en) 2016-06-22
EP3455249B1 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
CN109328196B (zh) 识别TGFβRII的移码突变体的T细胞受体
TWI835730B (zh) Ｔｃｒ及肽
KR102267345B1 (ko) Ｔ 세포 수용체
JP6726656B2 (ja) クローディン６特異的免疫受容体およびｔ細胞エピトープ
US20220119477A1 (en) Tcr and peptides
CN110036027A (zh) 新型t细胞受体及其免疫治疗应用
CN106749620B (zh) 识别mage-a1抗原短肽的t细胞受体
WO2016177339A1 (zh) 识别ny-eso-1抗原短肽的t细胞受体
KR20170140266A (ko) 클라우딘-18.2-특이적 면역수용체 및 t 세포 에피토프
IL314725A (en) Antibody/T-cell receptor chimeric structures and their uses
ES2749903T3 (es) Proteína quimérica
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
Matsuzaki et al. A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
WO2016184592A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof
US20230399402A1 (en) Hla class ii-restricted tcrs against the kras g12>v activating mutation
TWI843716B (zh) hTERT特異性結合分子
CN110272482A (zh) 识别prame抗原短肽的t细胞受体
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
CN108290940A (zh) Tcr及其用途
CN118215498A (zh) 末端脱氧核苷酸转移酶(TdT)的结合蛋白
CN115073584A (zh) 一种特异性识别prame抗原肽的tcr及其应用
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
EP4491630A1 (en) T-cell receptor for acute myeloid leukemia (aml)
EA042909B1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
EP4328239A1 (en) Immunotherapeutics based on magea1-derived epitopes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211221